Meet Embecta! Becton Dickinson Completes Diabetes Spin-Off
Executive Summary
Becton Dickinson has formally completed the planned spin-off of its diabetes business within the timeframe it projected about a year ago. The new company, called embecta, is one of the largest producers of diabetes injection devices.
You may also be interested in...
Becton Dickinson Sells Surgical Instrumentation To Steris For $540M
The divestiture is part of BD’s ongoing plan to cut 20% of its total product portfolio by 2025.
Medtech Challenged To Build On 2021 Amid Threats Of Recession: Views From Industry Leaders
Strong headwinds beset the medtech industry as 2022 draws to a close, including supply chain, fundraising and labor shortages. However, optimism prevailed among medtech industry leaders discussing EY’s annual Pulse of the Industry medical technology report and related topics at AdvaMed’s 2022 MedTech Conference.
Medtech Challenged To Build On 2021 Amid Threats Of Recession: Views From Industry Leaders
Strong headwinds beset the medtech industry as 2022 draws to a close, including supply chain, fundraising and labor shortages. However, optimism prevailed among medtech industry leaders discussing EY’s annual Pulse of the Industry medical technology report and related topics at AdvaMed’s 2022 MedTech Conference.